TRDA

Entrada Therapeutics, Inc.

Phase 2 Confirmed

ENTR-601-44

Duchenne muscular dystrophy

Resolved

61days ago

Phase 2 readout · May 7, 2026

What's at stake Phase 2 trial results for ENTR-601-44 in Duchenne muscular dystrophy are due May 7, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study.”

Add to calendar Post on X Reddit

Provenance